Background: Chronic lymphocytic leukemia (CLL) is the most common leukemia among adults in the world and it is characterized by a heterogeneous clinical course, ranging from stable to more aggressive disease. Methods: Total of 86 samples were included for the study. All the samples were studied for the various biomarkers (Interleukin-6, CRP, procalcitonin, LDH, Beta-2M, Ferritin, serum Amyloid and sTREM). Results: The highest prevalence rate found in CRP and LDH is 84 (97.67%) respectively, followed by Interleukin6 is 81 (94.18%), Ferritin is 79 (91.86%), Procalcitonin is 74 (86%), serum amyloid is 71 (82.55%), sTREM is 64 (74.41%), Beta-2-M is 53 (61.62%). Conclusions: Markedly elevated levels of IL-6, CRP, procalcitonin, LDH, Beta-2M, ferritin, serum amyloid A, and sTREM-1 were observed at the baseline stage in CLL patients, indicating significant inflammation and potential infection burden prior to chemotherapy initiation.